|
1
|
Santos ML, Pais AS and Almeida Santos T:
Fertility preservation in ovarian cancer patients. Gynecol
Endocrinol. 37:483–489. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
International Agency for Reaserch on
Cancer, Global Cancer Observatory, Cancer Today Globocan 2022, .
Ovary factsheet. https://gco.iarc.who.int/media/globocan/factsheets/cancers/25-ovary-fact-sheet.pdfFebruary
8–2024
|
|
3
|
Taylan E and Oktay K: Fertility
preservation in gynecologic cancers. Gynecol Oncol. 155:522–529.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
National Comprehensive Cancer Network, .
Ovarian Cancer (Version1.2017). https://www.nccn.org/professionals/phys-ician_gls/pdf/ovarian.pdfApril
15–2024
|
|
5
|
Arcieri M, Tius V, Andreetta C, Restaino
S, Biasioli A, Poletto E, Damante G, Ercoli A, Driul L, Fagotti A,
et al: How BRCA and homologous recombination deficiency change
therapeutic strategies in ovarian cancer: A review of literature.
Front Oncol. 14:13351962024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rasmussen CB, Kjaer SK, Albieri V, Bandera
EV, Doherty JA, Høgdall E, Webb PM, Jordan SJ, Rossing MA, Wicklund
KG, et al: Pelvic inflammatory disease and the risk of ovarian
cancer and borderline ovarian tumors: A pooled analysis of 13
Case-control studies. Am J Epidemiol. 185:8–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Seta F, Banco R, Turrisi A, Airoud M,
De Leo R, Stabile G, Ceccarello M, Restaino S and De Santo D:
Pelvic inflammatory disease (PID) from Chlamydia trachomatis versus
PID from Neisseria gonorrhea: From clinical suspicion to therapy. G
Ital Dermatol Venereol. 147:423–430. 2012.PubMed/NCBI
|
|
8
|
Barnard ME, Farland LV, Yan B, Wang J,
Trabert B, Doherty JA, Meeks HD, Madsen M, Guinto E, Collin LJ, et
al: Endometriosis typology and ovarian cancer risk. JAMA.
332:482–489. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim SY and Lee JR: Fertility preservation
option in young women with ovarian cancer. Future Oncol.
12:1695–1698. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lavoue V, Huchon C, Akladios C, Alfonsi P,
Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin
C, et al: Management of epithelial cancer of the ovary, fallopian
tube, primary peritoneum. Long text of the joint French clinical
practice guidelines issued by FRANCOGYN, CNGOF, SFOG,
GINECO-ARCAGY, endorsed by INCa. (Part 2: Systemic, intraperitoneal
treatment, elderly patients, fertility preservation, follow-up). J
Gynecol Obstet Hum Reprod. 48:379–386. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mangili G, Somigliana E, Giorgione V,
Martinelli F, Filippi F, Petrella MC, Candiani M and Peccatori F:
Fertility preservation in women with borderline ovarian tumours.
Cancer Treat Rev. 49:13–24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsonis O and Kopeika J: Fertility
preservation in patients with gynaecologic malignancy: Response to
ovarian stimulation and long-term outcomes. Eur J Obstet Gynecol
Reprod Biol. 290:93–100. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Akel RA, Guo XM, Moravek MB, Confino R,
Smith KN, Lawson AK, Klock SC, Tanner Iii EJ and Pavone ME: Ovarian
stimulation is safe and effective for patients with gynecologic
cancer. J Adolesc Young Adult Oncol. 9:367–374. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berek JS, Renz M, Kehoe S, Kumar L and
Friedlander M: Cancer of the ovary, fallopian tube, and peritoneum:
2021 update. Int J Gynaecol Obstet. 155 (Suppl 1):S61–S85. 2021.
View Article : Google Scholar
|
|
15
|
Alvarez M, Solé M, Devesa M, Fábregas R,
Boada M, Tur R, Coroleu B, Veiga A and Barri PN: Live birth using
vitrified-warmed oocytes in invasive ovarian cancer: Case report
and literature review. Reprod Biomed Online. 28:663–668. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mayeur A, Puy V, Windal V, Hesters L,
Gallot V, Benoit A, Grynberg M, Sonigo C and Frydman N: Live birth
rate after use of cryopreserved oocytes or embryos at the time of
cancer diagnosis in female survivors: A retrospective study of ten
years of experience. J Assist Reprod Genet. 38:1767–1775. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nitecki R, Clapp MA, Fu S, Lamiman K,
Melamed A, Brady PC, Kaimal A, Del Carmen MG, Woodard TL, Meyer LA,
et al: Outcomes of the first pregnancy after Fertility-sparing
surgery for Early-stage ovarian cancer. Obstet Gynecol.
137:1109–1118. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ledermann JA, Matias-Guiu X, Amant F,
Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C,
Leary A, Lorusso D, et al: ESGO-ESMO-ESP consensus conference
recommendations on ovarian cancer: Pathology and molecular biology
and early, advanced and recurrent disease. Ann Oncol. 35:248–266.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
NCCN Guidelines Version 1.2024, . Ovarian
Cancer/Fallopian Tube Cancer/Primary Perit. PubMed/NCBI
|
|
20
|
Armstrong DK, Alvarez RD, Backes FJ,
Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM,
Chitiyo VC, Cristea M, et al: NCCN Guidelines® Insights:
Ovarian cancer, version 3.2022. J Natl Compr Canc Netw. 20:972–980.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bentivegna E, Gouy S, Maulard A, Pautier
P, Leary A, Colombo N and Morice P: Fertility-sparing surgery in
epithelial ovarian cancer: A systematic review of oncological
issues. Ann Oncol. 27:1994–2004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zapardiel I, Cruz M, Diestro MD, Requena A
and Garcia-Velasco JA: Assisted reproductive techniques after
fertility-sparing treatments in gynaecological cancers. Hum Reprod
Update. 22:281–305. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tomao F, Di Pinto A, Sassu CM, Bardhi E,
Di Donato V, Muzii L, Petrella MC, Peccatori FA and Panici PB:
Fertility preservation in ovarian tumours. Ecancermedicalscience.
12:88520185PubMed/NCBI
|
|
24
|
Daraï E, Fauvet R, Uzan C, Gouy S,
Duvillard P and Morice P: Fertility and borderline ovarian tumor: A
systematic review of conservative management, risk of recurrence
and alternative options. Hum Reprod Update. 19:151–166. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Poulain M, Vandame J, Tran C, Koutchinsky
S, Pirtea P and Ayoubi JM: Fertility preservation in borderline
ovarian tumor patients and survivors. Horm Mol Biol Clin Investig.
43:179–186. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fortin A, Hazout A, Thoury A, Alvès K,
Bats AS, Dhainaut C and Madelenat P: Assistance médicale à la
procréation après traitement conservateur d'une tumeur de l'ovaire
invasive ou à la limite de la malignité Assisted reproductive
technologies after conservative management of borderline or
invasive ovarian tumours. Gynecol Obstet Fertil. 33:488–4897. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zaami S, Melcarne R, Patrone R, Gullo G,
Negro F, Napoletano G, Monti M, Aceti V, Panarese A, Borcea MC, et
al: Oncofertility and reproductive counseling in patients with
breast cancer: A retrospective study. J Clin Med. 11:13112022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rienzi L, Cobo A, Paffoni A, Scarduelli C,
Capalbo A, Vajta G, Remohí J, Ragni G and Ubaldi FM: Consistent and
predictable delivery rates after oocyte vitrification: An
observational longitudinal cohort multicentric study. Hum Reprod.
27:1606–1612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
SHRE Guideline Group on Female Fertility
Preservation, . Anderson RA, Amant F, Braat D, D'Angelo A, Chuva de
Sousa Lopes SM, Demeestere I, Dwek S, Frith L, Lambertini M, et al:
ESHRE guideline: Female fertility preservation. Hum Reprod Open.
2020:hoaa0522020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gullo G, Perino A and Cucinella G: Open vs
closed vitrification system: Which one is safer? Eur Rev Med
Pharmacol Sci. 26:1065–1067. 2022.PubMed/NCBI
|
|
31
|
Peccatori FA, Mangili G, Bergamini A,
Filippi F, Martinelli F, Ferrari F, Noli S, Rabaiotti E, Candiani M
and Somigliana E: Fertility preservation in women harboring
deleterious BRCA mutations: Ready for prime time? Hum Reprod.
33:181–187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gullo G, Basile G, Cucinella G, Greco ME,
Perino A, Chiantera V and Marinelli S: Fresh vs. frozen embryo
transfer in assisted reproductive techniques: A single center
retrospective cohort study and Ethical-legal implications. Eur Rev
Med Pharmacol Sci. 27:6809–6823. 2023.PubMed/NCBI
|
|
33
|
Park CW, Lee SH, Yang KM, Lee IH, Lim KT,
Lee KH and Kim TJ: Cryopreservation of in vitro matured oocytes
after ex vivo oocyte retrieval from gynecologic cancer patients
undergoing radical surgery. Clin Exp Reprod Med. 43:119–125. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ponce J, Fernandez-Gonzalez S, Calvo I,
Climent M, Peñafiel J, Feliubadaló L, Teulé A, Lázaro C, Brunet JM,
Candás-Estébanez B and Durán Retamal M: Assessment of ovarian
reserve and reproductive outcomes in BRCA1 or BRCA2 mutation
carriers. Int J Gynecol Cancer. 30:83–88. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oktay K, Kim JY, Barad D and Babayev SN:
Association of BRCA1 mutations with occult primary ovarian
insufficiency: A possible explanation for the link between
infertility and breast/ovarian cancer risks. J Clin Oncol.
28:240–204. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Oktay K, Turan V, Titus S, Stobezki R and
Liu L: BRCA mutations, DNA repair deficiency, and ovarian aging.
Biol Reprod. 93:672015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang ET, Pisarska MD, Bresee C, Chen YD,
Lester J, Afshar Y, Alexander C and Karlan BY: BRCA1 germline
mutations may be associated with reduced ovarian reserve. Fertil
Steril. 102:1723–1728. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kufel-Grabowska J, Podolak A, Maliszewski
D, Bartoszkiewicz M, Ramlau R and Lukaszuk K: Fertility counseling
in BRCA1/2-mutated women with breast cancer and healthy
individuals. J Clin Med. 11:39962022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Marklund A, Lekberg T, Hedayati E,
Liljegren A, Bergh J, Lundberg FE and Rodriguez-Wallberg KA:
Relapse rates and Disease-specific mortality following procedures
for fertility preservation at time of breast cancer diagnosis. JAMA
Oncol. 8:1438–1446. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim J, Turan V and Oktay K: Long-term
safety of letrozole and gonadotropin stimulation for fertility
preservation in women with breast cancer. J Clin Endocrinol Metab.
101:1364–1371. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Oktay K, Buyuk E, Libertella N, Akar M and
Rosenwaks Z: Fertility preservation in breast cancer patients: A
prospective controlled comparison of ovarian stimulation with
tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol.
23:4347–4353. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dias Nunes J, Demeestere I and Devos M:
BRCA mutations and fertility preservation. Int J Mol Sci.
25:2042023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tomao F, Peccatori F, Del Pup L, Franchi
D, Zanagnolo V, Panici PB and Colombo N: Special issues in
fertility preservation for gynecologic malignancies. Crit Rev Oncol
Hematol. 97:206–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Martinez A, Poilblanc M, Ferron G, De
Cuypere M, Jouve E and Querleu D: Fertility-preserving surgical
procedures, techniques. Best Pract Res Clin Obstet Gynaecol.
26:407–424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bruno M, Ludovisi M, Ronsini C, Capanna G,
Stabile G and Guido M: Tertiary cytoreduction for isolated
lymphnode recurrence (ILNR) ovarian cancer in a BRCA2 mutated
patient: Our experience and prevalence of BRCA 1 or 2 genes
mutational status in ILNR. Medicina (Kaunas). 59:6062023.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Restaino S, Finelli A, Pellecchia G,
Biasioli A, Mauro J, Ronsini C, Martina MD, Arcieri M, Della Corte
L, Sorrentino F, et al: Scar-free laparoscopy in BRCA-mutated
women. Medicina (Kaunas). 58:9432022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Madero S, Rodriguez A, Vassena R and
Vernaeve V: Endometrial preparation: Effect of estrogen dose and
administration route on reproductive outcomes in oocyte donation
cycles with fresh embryo transfer. Hum Reprod. 31:1755–1764. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bartsch E, Medcalf KE, Park AL and Ray JG:
Clinical risk factors for pre-eclampsia determined in early
pregnancy: Systematic review and Meta-analysis of large cohort
studies. BMJ. 353:i17532016. View Article : Google Scholar : PubMed/NCBI
|
